𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Extrahepatic malignancy following long-term immunosuppressive therapy of severe hepatitis B surface antigen-negative chronic active hepatitis

✍ Scribed by Kenneth K. Wang; Albert J. Czaja; Sandra J. Beaver; Vay L. W. Go

Publisher
John Wiley and Sons
Year
1989
Tongue
English
Weight
591 KB
Volume
10
Category
Article
ISSN
0270-9139

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Outcome of hepatitis B e antigen–negativ
Outcome of hepatitis B e antigen–negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine
✍ George V. Papatheodoridis; Evangelini Dimou; Konstantinos Dimakopoulos; Spilios 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 415 KB 👁 1 views

We determined the clinical outcome of hepatitis e antigen (HBeAg)-negative chronic hepatitis B patients treated with long-term nucleos(t)ide analog therapy starting with lamivudine. We evaluated 201 such patients treated for 3.8 ؎ 1.4 years and 2 historical similar cohorts: 1 treated with interferon

Long-term outcomes of thymosin-α1 and in
Long-term outcomes of thymosin-α1 and interferon α-2b combination therapy in patients with hepatitis B e antigen (HBeAg) negative chronic hepatitis B
✍ Murat Saruc; Nuri Ozden; Nurten Turkel; Semin Ayhan; Lynette M. Hock; Isil Tuzcu 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 179 KB 👁 1 views

Hepatitis B e antibody (HbeAb) and hepatitis B virus (HBV) DNA positive chronic hepatitis is a clinical entity, distinct from classical hepatitis B e antigen (HbeAg) positive chronic hepatitis B. Our aim was to evaluate the long-term therapeutic efficacy of the combination of interferon alpha-2b and

Severe acute exacerbation of liver disea
Severe acute exacerbation of liver disease may reduce or delay emergence of YMDD motif mutants in long-term lamivudine therapy for hepatitis B e antigen-positive chronic hepatitis B
✍ Akihito Tsubota; Yasuji Arase; Fumitaka Suzuki; Mariko Kobayashi; Marie Matsuda; 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 98 KB

## Abstract The pretherapy factors that could influence the emergence of resistant hepatitis B virus (HBV) tyrosine‐methionine‐aspartate‐aspartate (YMDD) motif mutants against lamivudine are not fully known in prolonged lamivudine therapy for hepatitis B e antigen (HBeAg)‐positive chronic hepatitis